PubMed Health⌕ Search

Biomedical subjects

F Trux

Publications and source records attributed to F Trux.

At least 19 recordsLinked to original sources
PubMed1990

[Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group].

In a multicentre phase II trial, 20 patients with advanced pancreatic carcinoma were treated with 5-fluorouracil, 4-epidoxorubicin and mitomycin C, in which 4-epidoxorubicin was administered by escalated dose and split course (FEM II). From among 12 patients evaluable for response, 2 partial and 1 minimal remission were observed, suggesting a response rate of 25%. Four patients (30%) showed a no change and 5 progression. The median survival of all patients was 3.4 months, of the responders 8.4 months, of those with no change 5.2, and of those showing progression 3.4 months. Considerable nausea/vomiting and leukopenia was observed. The preliminary data suggest that the FEM II regimen does not offer any progress in terms of efficacy, survival and toxicity for advanced pancreatic carcinoma.

Adult↗
PubMed1984

[Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].

In a multi-center study of 77 patients with gastric carcinoma and metastases, the effects of combined 5-fluorouracil and carmustine with or without adriamycin (FB vs FAB) were compared. There was no significant difference between the two treatment groups as to rate of response or survival time, response to treatment was 20% (FB) and 24% (FAB), including "no change" 52% and 56%, respectively. But median survival time among the responders (partial remission and clinical improvement) and of the patients with unchanged findings was significantly longer (8.4 or 7.4 months, respectively) than that among patients with progression (4.5 months). Analysis of prognostic factors in terms of survival curves revealed no difference between patients with or without measurable tumor parameters, with or without local recurrences or liver metastases. However, there was a statistically significant worsening of prognosis for patients whose initial general state was reduced, who had lung metastases or increased WBC counts. Side effects were relatively mild with both therapy regimens, except for alopecia with FAB. After the second treatment cycle myelosuppression was more marked with FAB than FB.

Adult↗
PubMed1983

Polypectomy in the presence of portal hypertension--an increased risk of bleeding?

A report is presented on 58 polypectomies performed in the stomach and colorectum in 46 patients. Twenty-five patients had portal hypertension consequent on liver cirrhosis, while 21 patients had healthy livers. The question as to whether haemorrhage occurred immediately after polypectomy or within the next 24 hours, was investigated. Furthermore, either the stalk (of pedunculated polyps), or the polyp itself (when sessile) was investigated pathologically-anatomically, with respect to its vascularity pattern. The submucosal and intramucosal vascularity patterns were classified in 4 categories, I to IV. A tentative interpretation of the results obtained indicates, on the basis of their mucosal and submucosal vascularity patterns, that patients with portal hypertension developing from a cirrhosis of the liver, are not at any higher risk of haemorrhage than patients with no portal hypertension.

Adult↗
PubMed1978

[The appearance of immature cell leukemias after radiologic and cytostatic intensive therapy of Hodgkin's lymphoma].

Among 106 patients with Hodgkin's lymphoma in stage IIIB and IVB treated from September 1969 to June 1977 by a working team for hematology and oncology at the clinic and outpatients clinic of the Medical School of Erfurt, there were two cases (=1.9%) showing a final transition to leukaemia with immature cells. A third neoplasia which had developed in a former field of irradiation was additionally observed in one patient. The various possibilities arising from an oncologic effect of ionizing rays and those substances having a cytostatic effect are discussed. After frequent reports on the occurrence of secondary tumours following intensive radiological and cytostatic therapy of advanced Hodgkin's lymphoma the enhanced risk of a secondary tumour being induced by this combined therapy cannot be excluded. Various conclusions are drawn from that by the authors.

Cyclophosphamide↗
PubMed1977

[Stem-cell leukoses in the adult age--a clinical study].

The cytochemical differentiation of 86 stem cell leucoses of adults resulted with 74% of the cases in a clear prevalence of PAS-negative forms at this age. PAS-positive leucoses were observed only in 11%. The survival time of the patients revealed a clear dependence of the degree of the remission achieved. Also for the cases of PAS-negative leucoses, which achieved a complete remission, it was not worse than the survival time of acute lymphoplastic leucoses. However, the remission coefficient of the PAS-negative leucoses was essentially below the value of lymphoblastic forms. Multiple cytostatic combinations reached the best remission rates. Above all the combination of ribidomycin, cytosine arabinosid (Alexan), 6-mercaptopurine (Mercaleukin), prednisolone and vincristine (Oncovin), called RAMPO-scheme by the authors, seemed to give much success according to the results of this study. The number of complete and good partial remissions was calculated with 62% for the ViDaP-scheme, with 51% for the COAP-scheme. For all cases of treatment the coefficient of remission was 54%.

Adolescent↗
PubMed1977

[Pararheumatic diseases in leukoses].

Pararheumatic complaints may be the leading clinical symptom in the individual case also in leucoses and may lead to diagnostic errors. They are caused by leucotic infiltrates in juxta-articular bone segments, sporadically also by blast infiltrates of the synovial membrane, by secondary osteoporoses or osteoscleroses and by articular haemorrhages. In altogether 254 patients with leucosis there were rheumatoid symptoms in 21% of the cases with undifferentiated cell leucoses, in 37% of the cases with chronic myelosis, and in 12% of the cases with chronic lymphadenosis. Diagnostic errors are deplorable above all in the undifferentiated cell leucosis, as every temporary retardation of the beginning of the therapy furthermore deteriorated the prognosis of the disease.

Diagnosis, Differential↗
PubMed1976

[Problems in the treatment of stem cell leukemias in aged patients].

Stem-cell leukemias will reveal a second peak of frequency at old age. The cytochemical differentiation in 26 patients of old age revealed a preponderance of myeloblastic forms. Moreover, a slight accumulation of monocytic and myelo-monocytic types could also be observed. In spite of this apparently unfavourable cytochemical differentiation the relatively good capability of myeloblastic leukemias of responding to cytostatic treatment was surprising. However, no cytostatic maximum programmes should be chosen in view of the low regenerating ability of the bone marrow in old patients.

Aged↗
PubMed1976

[Splenectomy in Hodgkin's disease--indication and results (author's transl)].

The spleen is involved in 20-30 percent of patients with Hodgkin's disease. Involvement of the spleen cannot be excluded with reliability by radiological procedures or clinical chemistry. Therefore laparotomy and splenectomy are recommended as staging and therapeutic measures. In the authors's material, splenectomy showed splenic lesions in 9 out of 21 patients, mostly unexpected. Splenectomy is always indicated in stage II and should be taken into consideration in individual cases of stages I and III, too.

Adolescent↗